Allakos Inc. (ALLK) News

Allakos Inc. (ALLK): $1.11

0.08 (+7.77%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add ALLK to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#194 of 347

in industry

Filter ALLK News Items

ALLK News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ALLK News From Around the Web

Below are the latest news stories about ALLAKOS INC that investors may wish to consider to help them evaluate ALLK as an investment opportunity.

Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q3 2023

Financial Highlights and Business Updates from Allakos's Latest Earnings Filing

Yahoo | November 13, 2023

Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results

SAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2023. Recent Allakos Events Completed enrollment in both the Phase 2 study of subcutaneous lirentelimab in patients with atopic dermatitis and the Phase 2b study of subcutaneous

Yahoo | November 13, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping tabs on for Thursday morning!

William White on InvestorPlace | November 9, 2023

Following a 63% decline over last year, recent gains may please Allakos Inc. (NASDAQ:ALLK) institutional owners

Key Insights Given the large stake in the stock by institutions, Allakos' stock price might be vulnerable to their...

Yahoo | November 6, 2023

Why Shares of Allakos Are Up Wednesday

Shares of clinical-stage biotech company Allakos (NASDAQ: ALLK) were up more than 15% as of 11:40 a.m. on Wednesday. Despite the rise, Allakos' stock is still down more than 70% so far this year. Allakos focuses on monoclonal antibodies to trigger responses in the body's immune cells to treat various conditions, including allergies, and inflammatory and proliferative diseases.

Yahoo | September 27, 2023

Allakos Appoints Neil Graham to its Board of Directors

SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Neil Graham, M.D. to the Allakos board of directors. Dr. Graham was the Chief Medical Officer of Tiziana Life Sciences Limited and currently serves on the board of directors of Aslan P

Yahoo | August 30, 2023

Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results

SAN CARLOS, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2023. Recent Allakos Events Presented preclinical data at the European Academy of Allergy and Clinical Immunology (“EAACI”) Hybrid Congress 2023 highlighting lirentelimab and AK006

Yahoo | August 9, 2023

Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors

SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Rand Sutherland, M.D. and Dolca Thomas, M.D. to the Allakos board of directors. Dr. Sutherland was the Chief Executive Officer of Seeker Biologics, a privately-held company, and curren

Yahoo | August 2, 2023

Companies Like Allakos (NASDAQ:ALLK) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | August 2, 2023

Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition

– AK006 inhibits IgE mediated mast cell activation and shows similar IgE inhibitory activity as remibrutinib –– AK006 also inhibits non-IgE mast cell activation pathways, including KIT-mediated activation– SAN CARLOS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announc

Yahoo | June 12, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!